3317 |
Will Long Term Dual Antiplatelet Therapy Improve LT Outcome? |
Roxana Mehran |
Apr. 20. 15 |
3316 |
[Lesson 1: STENT] What is the Difference Among Various Stents? |
Masahiko Fujihara |
Apr. 20. 15 |
3315 |
Remnant Risk of Secondary MACE/ Mortality After Index AMI in Asian Patients |
Kiyuk Chang |
Apr. 20. 15 |
3314 |
Does True Vessel Healing Matter? |
Roxana Mehran |
Apr. 20. 15 |
3313 |
Remnant Risk of Secondary MACE/ Mortality After Index AMI |
Freek W.A. Verheugt |
Apr. 20. 15 |
3312 |
Does Lesion Preparation Matter? |
Kentaro Jujo |
Apr. 20. 15 |
3311 |
Optimal Duration of Dual Antiplatelet Therapy After Implantation of DES: Shorter or Longer? |
Jang-Whan Bae |
Apr. 20. 15 |
3310 |
How Do I Manage My Most Complex CTO? |
Satoru Sumitsuji |
Apr. 20. 15 |
3309 |
Antiplatelet Therapy in ACS: Are New Pharmacological Agents Changing Paradigms Beyond Clopidogrel? |
Soon Jun Hong |
Apr. 20. 15 |
3308 |
Safety Assured: Global Resolute Data |
Rosli Mohd Ali |
Apr. 20. 15 |